FindTrial
Sign In

Inclacumab

DRUG7 trials

Sponsors

Hoffmann-La Roche, Pfizer, Global Blood Therapeutics Inc, A wholly owned subsidiary of Pfizer Inc

Conditions

Haematological Disorders Sickle Cell DiseaseHealthy VolunteerSickle Cell DiseaseVaso-occlusive CrisisVaso-occlusive Pain Episode in Sickle Cell Disease

Phase 1

A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers
CompletedNCT01815827
Hoffmann-La RocheHealthy Volunteer
Start: 2013-06-30End: 2014-02-28Updated: 2016-11-02

Phase 3

GBT2104-132
RecruitingPACTR202106894720601
Global Blood Therapeutics IncHaematological Disorders Sickle Cell Disease
Start: 2021-07-01Target: 280Updated: 2026-08-03
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
TerminatedNCT04927247
PfizerSickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Start: 2021-12-09End: 2023-11-24Updated: 2024-12-11
GBT2104-131
RecruitingPACTR202106511293049
Global Blood Therapeutics IncHaematological Disorders Sickle Cell Disease
Start: 2021-06-01Target: 240Updated: 2026-08-03
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
CompletedNCT04935879
PfizerSickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Start: 2021-10-04End: 2024-06-06Updated: 2025-12-02
GBT2104-133(C5361003)
Active, not recruitingPACTR202108532761448
A wholly owned subsidiary of Pfizer IncHaematological Disorders Sickle Cell Disease
Start: 2021-10-01Target: 520Updated: 2026-08-03
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
TerminatedNCT05348915
PfizerSickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Start: 2022-03-29End: 2025-11-07Updated: 2025-12-17

Related Papers

A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease
European Journal of Clinical Pharmacology2023-07-1211 citations
5572697 TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE
HemaSphere2023-04-012 citations
TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE
Hematology Transfusion and Cell Therapy2022-10-011 citations
P1486: TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE
HemaSphere2022-06-014 citations